Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Disopyramide is a class 1A antiarrhythmic agent used to treat life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia. It works by inhibiting fast sodium channels in cardiac myocytes, thereby decreasing the rate of diastolic depolarization (phase 4), reducing the upstroke velocity (phase 0), and increasing the action potential duration in normal cardiac cells. This results in increased resistance of the heart to abnormal electrical activity and helps restore normal rhythm. Disopyramide also has anticholinergic and local anesthetic properties but does not block alpha- or beta-adrenergic receptors[1][3][5][6]. Its primary indication is for documented ventricular arrhythmias that are potentially life-threatening.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on disopyramide.